Introduction
Primary Sjö gren's syndrome (SS) is a chronic autoimmune inflammatory disease with an estimated prevalence of 0.5% among Caucasian women and a female to male ratio of about 9:1.
1 Primary SS is characterized by focal lymphocytic infiltrates of the salivary and lacrimal glands resulting in decreased salivary flow and dry eyes. Arthritis, lymphadenopathy, major salivary gland swelling, leucopenia and a low grade fever are among the disease manifestations in primary SS and there is a 15-fold increased risk for lymphoma development. 2 Compared with unrelated individuals, first degree relatives of patients with primary SS have an increased incidence of primary SS and of the closely related autoimmune disease systemic lupus erythematosus (SLE), other autoimmune diseases and immunological abnormalities. 3 There are case reports on twins with concordance for primary SS, 4 but the heritability has not been systematically estimated. The genetics of primary SS has been sparsely addressed and no genome wide linkage studies or genome-wide association studies (GWAS) have so far been published.
Among the histocompatibility leukocyte antigen (HLA) haplotypes, HLA-DRB1*0301, -DQA1*0501 and -DQB1*0201 have been consistently associated with primary SS in Caucasians. 5 Associations between primary SS and genes outside the HLA region have been investigated, but these studies were often performed in small cohorts with conflicting results or lack of replication, for a review, see reference. 6 These early studies detected associations with single-nucleotide polymorphisms (SNPs) in the interleukin 10 (IL10) promoter, Fas/FasL and with SNPs in the TGFb1 and TNFa genes in primary SS patients with anti-SSB antibodies.
Recently, polymorphisms in two genes in the type I interferon (IFN) system, the interferon regulatory factor 5 (IRF5) gene on chromosome 7q32.1 and the signal transducer and activator of transcription 4 (STAT4) gene on chromosome 2q32.3, have been convincingly associated and replicated as risk factors for primary SS. [7] [8] [9] Polymorphisms in IRF5 are also associated with SLE, rheumatoid arthritis (RA), systemic sclerosis (SSc), inflammatory bowel diseases and multiple sclerosis, indicating that polymorphisms in IRF5 contribute to general autoimmunity. [10] [11] [12] [13] [14] An association with STAT4 was first identified in SLE and RA, and later replicated in SSc, inflammatory bowel diseases, type 1 diabetes, psoriasis and recently also in primary antiphospholipid antibody syndrome. [15] [16] [17] [18] [19] Analogously with SLE, the type I IFN system is activated in primary SS, 20 as indicated by gene expression profiles of peripheral blood cells and minor salivary glands from primary SS patients, which display upregulation of type I IFN induced genes, a so called 'IFN signature'. [21] [22] [23] The aim of this study was to identify SNPs in candidate genes with a putative role in the immune pathogenesis of primary SS. In the study, we included genes in the type I IFN system, genes involved in the inflammatory process in the minor salivary glands and lymphoma development and genes associated with systemic inflammation. Given the clinical and serological similarities between primary SS and SLE, and the association with IRF5 and STAT4 in both diseases, genes identified in GWAS of SLE were also included because of their potential involvement in primary SS.
Results
In our study, we included 84 candidate genes that were selected based on their possible biological roles in the pathogenesis of primary SS or because they have been associated with SLE in GWAS studies (Table 1) . For full names of the genes included and their chromosomal locations, see Supplementary Table 1 . For each of the 84 genes we selected tag-SNPs to capture most of the common genetic variation and additional SNPs that were of interest because of their previously shown association with other autoimmune diseases. The selected SNPs were genotyped in two independent cohorts of patients with primary SS and healthy controls from Sweden and Norway. After genotype quality control, 540 patients with primary SS, of which 344 were from Sweden and 196 from Norway (Table 2 ) and 532 controls, of which 319 were Swedish and 213 were Norwegian, remained for analysis. A total of 1139 SNPs in 84 genes passed quality control and were subjected to association analysis in the Swedish and Norwegian cohorts. Figure 1 shows the overall results from the combined association analysis in the Swedish and Norwegian cohorts. The genotype and association data for the SNP with lowest P-value in each of the 84 genes are provided in Supplementary Table 2 .
Combined analysis of the Swedish and Norwegian cohorts identified SNPs with association signals with nominal P-values o0.001 in three gene loci, for which no association with primary SS has previously been reported, the early B-cell factor 1 (EBF1) gene on chromosome 5q34, the family with sequence similarity 167, member A (previously denoted C8 open reading frame 13)-B-lymphoid tyrosine kinase (FAM167A-BLK) locus on chromosome 8p23.1 and the tumor necrosis factor superfamily member 4 (TNFSF4 ¼ Ox40L) gene on chromosome 1q25.1 (Table 3) . AICDA  CCL19  CXCR2  IL15RA  LTBR  STAT4  BANK1  CCL21  CXCR3  IL1R1  MDM2 TANK  BLK  CCL5  CXCR4  IL4  NFKB1  TLR4  BCL2  CCR7  EBF1  IL4R  NLRP1  TNFRSF4  BCL2L11 CD14  FAM167A  (C8orf13)   IL5  NLRP3  TNFSF4   BCL6  CD40  FOXP3  IL6  NRP1  TNFSF13  C3  CD40 L HSP90AB1 IL7  PARP1  TNFSF13B  C4A  CD46  HSPA5  IL8  PDCD1 TNPO3  CA1  CHRM1 HSPD1  IRAK1  PRDM1 TP53  CA2  CR1  HSPE1  IRF8  PTPN22 TRAF6  CA4  CTLA4  ICA1  ITGAM  PXK  TYK2  CA6  CXCL6  IFIH1  ITGAX  SDC1  UBE2L3  CARD8  CXCL10 IKBKE  KIAA0495 STAT1  UBLCP1  CCL11  CXCR1 IL10  KIAA1542 STAT3  VEGFA   a   For full names, see Supplementary Material, Supplementary  Table S1 . Table 3 Genes associated with primary Sjö gren's syndrome in the Swedish and Norwegian cohorts 
EBF1, BLK, TNFSF4 polymorphisms in primary SS G Nordmark et al
By analyzing 66 SNPs in EBF1, we identified a strong association signal for the SNP rs3843489 in the tenth intron of EBF1, in both the Swedish and Norwegian cohorts, as well as in the combined analysis of data from both cohorts, with P ¼ 9.9 Â 10 À5 and odds ratio (OR) 1.68 (95% confidence interval (CI) 1.29-2.18). In addition, the SNP rs869593 in the sixth intron of EBF1 showed an association with P ¼ 2.0 Â 10 À3 and OR 1.35 (95% CI 1.12-1.64) in the combined analysis of the Swedish and Norwegian cohorts (Supplementary Table 3 ). Figure 2a shows the structure of the EBF1 gene and highlights the location of the two SNPs that yielded association signals with primary SS. The EBF1 gene is located in a region of low linkage disequilibrium (LD) (Supplementary Figure  1a) . The association signals from the two SNPs in EBF1 appear to be independent. The LD between the SNPs rs3843489 and rs869593 is low (r 2 ¼ 0.12) and regression analysis conditional on the SNP rs869593 did not abolish the association signal from the SNP rs3843489 (Supplementary Table 4 ). Supplementary Table 3 provides the association data for the 66 analyzed SNPs in EBF1.
By analyzing 80 SNPs in the FAM167-BLK locus we detected association signals with primary SS from the SNPs, rs12549796 in the second intron of FAM167A and rs12677843 in the large first intron of BLK, at Po0.001 in the combined Swedish and Norwegian cohorts. These SNPs are in intermediate LD (r 2 ¼ 0.29). Eight additional SNPs in this region showed suggestive association signals with Po0.01 (rs11250135, rs6998387, rs11779875, rs2898280, rs2736340, rs13277113, rs4841550 and rs2248932) and 16 SNPs had nominal P-values o0.05 (Supplementary Table 3 ). The association between primary SS and SNPs in the FAM167A-BLK locus was particularly strong in the Norwegian cohort. Figure 2b shows the structure of the FAM167A-BLK locus and the location of the SNPs, for which we detected association signals with primary SS. The pairwise LD-structure is depicted in Supplementary Figure 1b . The highly linked (r 2 ¼ 0.98) SNPs rs2736340 and rs13277113, located in the intergenic region between the FAM167A and BLK genes were associated with primary SS with a combined P ¼ 1. In the TNFSF4 gene, we analyzed 11 SNPs and identified 2 linked (r 2 ¼ 0.83) SNPs in the 5 0 -UTR region, rs1234315 (Po0.001) and rs1234314 (Po0.01), associated with primary SS in the combined analysis of the Swedish and Norwegian cohorts. In addition, the SNP rs704840, which is located upstream in the 5 0 -UTR region, but is in lower LD with the SNP rs1234315 (r 2 ¼ 0.37), compared with the SNP rs1234314, showed an association with Po0.001 in the combined cohort (Figure 2c , Supplementary Table 3 and Supplementary Figure 1c) . The association between primary SS and TNFSF4 was stronger in the Swedish cohort than in the Norwegian cohort, but in the combined analysis of the two cohorts, the overall significance of the association was strengthened.
In an attempt to refine our previously shown association signal between the SNP rs10488631 in the IRF5-TNPO3 locus on chromosome 7q32.2 and primary SS, 9 we analyzed eight SNPs in the TNPO3 gene, of which seven are in low LD (r 2 o0.17) with the SNP rs10488631 located in the 3 0 -UTR of IRF5. The strongest association signal (P ¼ 5.5 Â 10
À6
) in the combined Swedish and Norwegian cohorts was observed for the SNP rs13246321 in the TNPO3 gene, which is in perfect LD with the SNP rs10488631 (r 2 ¼ 1), whereas the seven other SNPs in TNPO3 did not show any signals of association with primary SS. Thus, these results confirm our previous finding of a strong association between SNPs in the 3 0 end of IRF5 and primary SS. We also confirmed our recently reported association between the SNP rs7582694 in the STAT4 gene on chromosome 2q32.3 and primary SS in the combined Swedish and Norwegian cohort. 9 In addition, we found suggestive association signals with Po0.01 in the combined cohort, from SNPs in seven genes that have not previously been associated with primary SS. These are the genes encoding the B cell surface antigen CD40, the islet cell autoantigen 1 (ICA1), the monocyte differentiation antigen CD14, the B-cell lymphoma 2 (BCL2) protein, the nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NFKB1), the CD40 ligand (CD40L) and the complement component 4A (C4A) ( Table 3) .
We only observed weak associations (Po0.05), between primary SS and the interleukin 1 receptorassociated kinase 1 (IRAK1), interleukin 10 (IL10) and KIAA1542 genes, which were included in our study, because of their reported associations with SLE. [24] [25] [26] We also observed a weak association, P ¼ 0.015 in the combined cohort, with the leucine rich repeat and pyrin domain containing 3 (NLRP3) gene, also known as NALP3 or cryopyrin, which is part of the NLRP3 inflammasome in the innate immune system and has been associated with RA and Crohn's disease. 27, 28 The B lymphocyte activating factor (BAFF ¼ TNFSF13B) gene was not associated with primary SS in a previous study. 29 Concordantly, we only observed a weak association signal from BAFF, (P ¼ 0.035), analyzing the combined data from the Swedish and Norwegian cohorts. We did not find any association between primary SS and SNPs in the BANK1, ITGAM-ITGAX or PXK genes (Supplementary Table 2 ) that have been convincingly associated with SLE in recent GWAS. 24, 30, 31 In our study, we had 68-92% Patients with primary SS that are positive in sera for the anti-SSA autoantibodies alone or in combination with anti-SSB, are more likely to have a systemic disease with extraglandular manifestations compared with anti-SSA/ anti-SSB negative patients. 3 We therefore, initially chose to compare the risk allele frequencies for the SNPs that gave the highest signals of overall association with primary SS, in the TNPO3, EBF1, FAM167A-BLK, STAT4, TNFSF4, CD40, ICA1, CD14, BCL2, NFKB1, CD40L and C4A genes, between patients that were positive for anti-SSA and/or anti-SSB antibodies (n ¼ 391) and patients that were antibody negative (n ¼ 141). In this case-only analysis, we found a weak association between autoantibody status and C4A (P ¼ 0.017) and a tendency for an association between antibody positivity and TNFSF4 (P ¼ 0.058) in a combined analysis of the two cohorts (Supplementary Table 5 ). We then analyzed the whole dataset of 1139 SNPs and compared the risk allele frequencies between the antibody positive patients (n ¼ 391) with the risk allele frequencies in the healthy controls (n ¼ 532). In this case-control analysis, the association signals for TNFSF4 and C4A were strengthened by one order of magnitude. In addition, SNPs in the IKBKE, STAT1, NLRP3 and IL10 genes now showed an association with primary SS with Po0.01 (Table 4) . Phenotype data regarding extraglandular manifestations including lymphoma and hypergammaglobulinemia, was obtained from the patient files and tested for association with the best SNPs in EBF1, FAM167A-BLK and TNFSF4. We found no convincing association between these SNPs and extraglandular manifestations (Supplementary Table 6 ).
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Discussion
Our study identified variants of the EBF1 gene, the FAM167A-BLK locus and the TNFSF4 gene as novel risk factors for primary SS. This is interesting as EBF1, BLK and TNFSF4 are all involved in B-cell development and activation. Polymorphisms in the EBF1 gene have not previously been associated with any rheumatic autoimmune disease. Apart from associations with acute leukemia of B cell origin, solely an association with multiple sclerosis has been described previously for EBF1. 32, 33 In B-cell leukemia, deletions in, as well as complete loss of the EBF1 gene have been observed in tumor cells.
Associations of SNPs in the FAM167A-BLK locus were first detected in SLE in two GWAS in early 2008. 24, 30 The initial association with SLE described in Caucasians has now been replicated in both Japanese and Chinese populations. 34, 35 Recently, association between the FAM167A-BLK locus and RA in both Japanese population and in Caucasians have been suggested. However, another study in Caucasians did not find this association with RA. [36] [37] [38] The FAM167A-BLK locus is also associated with SSc and primary antiphospholipid antibody syndrome. 18, 39, 40 Like IRF5, STAT4 and FAM167A-BLK, the TNFSF4 gene was first reported to be associated with SLE in both Caucasians and Asians, and recently TNFSF4 was also found to be associated with SSc. [41] [42] [43] An association between a TNFSF4 polymorphism and atherosclerosis has also been reported. 44 The EBF1, BLK and TNFSF4 genes are all involved in B-cell development and activation in different ways. EBF1 encodes the transcription factor EBF1, also known as protein Collier, Olf and EBF transcription factor 1, which is one of the most important transcription factors for B-cell development. EBF1 enhances transcriptional activity by initiating demethylation of DNA and is necessary for the activation of PAX5, a gene required for the expression of B-cell markers, including immunoglobulins. The lack of EBF1 results in arrest of B-cell development in mice. 45 EBF1 is expressed in multiple tissues including progenitor and mature B cells, plasmacytoid dendritic cells, bone marrow stromal cells, adipocytes and forebrain neurons and binding sites for EBF1 have been identified in promoters of multiple genes, including BLK. 46 The deletions of EBF1 observed in tumor cells in acute lymphoblastic leukemia of B cell origin 33 suggests that reduced expression of EBF1 may contribute to the aberrant B-cell development in this form of leukemia.
The tyrosine kinase BLK is mainly expressed in B cells and is activated during B-cell receptor signaling, which further activates nuclear transcription factors through a signaling cascade. The risk allele (A-allele) of the SNP rs13277113 is correlated with the expression levels of the FAM167A and BLK genes, which are transcribed in opposite directions, where decreased expression of BLK and increased expression of FAM167A in transformed B cells has been demonstrated. 30 According to allelic association mapping the intergenic region between FAM167A and BLK may represent an independent, yet unannotated transcript regulated by a different haplotype than the expression of FAM167A and BLK. 47 Hypothetically, reduced BLK expression in early development might affect tolerance, allowing self-reactive B cells to escape deletion, but further functional studies are warranted to clarify the consequences of the multiple polymorphisms within this gene. The function of the protein encoded by FAM167A is unknown. TNFSF4 (Ox40L, CD252) is a cytokine expressed on the surface of antigen presenting cells, including B cells and plasmacytoid dendritic cells, T cells, natural killer cells and vascular endothelial cells. Binding of TNFSF4 to the TNFSF4 receptor (TNFRSF4, Ox40, CD136) on T cells, transmits co-stimulatory signals, which results in T-cell proliferation and cytokine production. The TNFSF4-TNFRSF4 interaction has been shown to inhibit the generation of IL-10 producing regulatory T cells, and type I IFN-producing plasmacytoid dendritic cells together with TNFSF4 promotes a T helper cell 1 response. 48 Functional studies in lymphoblastoid cell lines expressing the risk haplotypes in SLE for TNFSF4, demonstrated an increased mRNA expression and cell surface protein expression of TNFSF4 after activation, compared with cells with the non-risk haplotype. 42 Consequently, the identified SNPs in the promoter region may lead to increased TNFSF4-TNFRSF4 signaling thereby contributing to autoimmune diseases.
We also detected a suggestive association between a SNP in the gene encoding CD40 (TNFRSF5), a co-stimulatory molecule expressed on B cells, macrophages, EBF1, BLK, TNFSF4 polymorphisms in primary SS G Nordmark et al Minor allele based on the whole cohort of cases and controls.
d Unadjusted P-value for differences in allele frequencies between patients and controls.
e Combined P-value calculated using Cochran-Mantel Haenszel w 2 -test. Results for the best SNP/gene with a P-value of o0.01 in the combined analysis is shown. The CD40  ligand, CD40L (TNFSF5, CD154 ) is expressed on CD4 þ Th cells and the CD40-CD40L interaction is important for B-cell activation, differentiation, germinal center formation and immunoglobulin switch, and also for T-cell proliferation. 49 An expression of CD40 in the epithelial cells in the minor salivary glands of patients with primary SS has also been described. 50 Polymorphisms in CD40 has been described in patients with acute coronary artery syndrome, thyroiditis, lymphoma and RA, [51] [52] [53] but has failed to show an association with SLE. 25, 54 This is the first reported suggestive association between a CD40 polymorphism and primary SS.
EBF1, BLK, TNFSF4 polymorphisms in primary SS
B cells have an important role in the immune pathogenesis of primary SS 55 and the association between primary SS and SNPs in EBF1, BLK and TNFSF4, and the suggestive association with CD40, is intriguing. The focal lymphocytic infiltrations in the minor salivary glands consist mainly of T cells with variable numbers of B cells and plasma cells, but few dendritic cells. The presence of plasmacytoid dendritic cell and IFN-a has also been demonstrated. 20, 22 The pleiotropic immunomodulatory effects of IFN-a includes increased B-cell receptor signaling, B-cell differentiation and enhanced antibody production. In about 30% of the lymphocyte foci, germinal center-like structures can form, with B cells and follicular dendritic cells characteristic of a secondary lymphoid follicle with local autoantibody synthesis including anti-SSA/Ro and anti-SSB/La antibodies. 56 The presence of germinal center-like structures indicates a certain disease phenotype reflected by a different serological and cytokine profile. 57 The presence of autoantibodies in sera in about 75% of primary SS patients and hypergammaglobulinemia in about 50% of patients indicates increased B-cell activity. 55 Also, the lymphomas seen in primary SS patients are mainly diffuse large B-cell lymphomas and B-cell lymphomas arising from mucosa-associated lymphoid tissue. 2 Thus, it seems plausible that polymorphisms in EBF1, FAM167A-BLK, TNFSF4 and possibly CD40, which all are involved in immune regulation, together with the previously described polymorphisms in IRF5 and STAT4 in the type I IFN system, [7] [8] [9] contribute to the pathogenesis and development of primary SS.
We found no convincing association between autoantibody status and SNPs in the genes, for which we observed association signals with primary SS. In anti-SSA/anti-SSB negative patients, a positive minor salivary gland biopsy with focal lymphocytic infiltrates is required for the classification of primary SS. 58 Therefore, the polymorphisms we identified in our study may well be associated with the disease itself, with autoimmune reactions in tissues, regardless of autoantibody status. Likewise, we found no association between the best SNPs in EBF1, FAM167A-BLK, TNFSF4 and clinical manifestations, including B-cell-related manifestations, such as lymphoma and hypergammaglobulinemia. This could possibly be due to lack of power in our case-case analysis. Several genes are now emerging as general autoimmune genes associated with different diseases, including autoimmune rheumatic diseases. IRF5, STAT4, FAM167A-BLK and TNFSF4 are associated with SLE, primary SS and SSc, and IRF5 and STAT4 are also convincingly associated with RA. It is noteworthy that some genes we analyzed, PXK, ITGAM-ITGAX and BANK1, that have been associated with SLE, did not show an association with primary SS. This indicates that different constellations of susceptibility genes contribute to the disease phenotype. Our study also describes differences between the Swedish and Norwegian cohorts regarding the minor allele frequencies for SNPs in some of the genes. This highlights the fact that although neighboring Scandinavian countries, there are genetic population differences, which have to be taken into account when performing association studies. A fine mapping of the genetic structure in Europe confirms this genetic variation. 59 In summary, our study, which is the largest genetic association study performed so far in primary SS, identified association signals for SNPs in three loci, EBF1, FAM167A-BLK and TNFSF4. Future studies of the functional consequences of polymorphisms in these three gene loci, which all are involved in B-cell differentiation and activation are needed in order to understand the molecular disease mechanisms in the development of primary SS.
Materials and methods

Patients and controls
A total of 605 patients with primary SS and 596 controls were included in this study. Out of these, a total of 368 primary SS patients, 228 Swedish and 140 Norwegian, and 148 Norwegian controls, were also included in our previous study. 9 The patients originate from the rheumatology clinics at the Malmö (n ¼ 169), Linkö ping (n ¼ 65) and Uppsala (n ¼ 80) University Hospitals and the Karolinska University Hospital in Stockholm (n ¼ 79), Sweden, and the rheumatology clinics at Haukeland University Hospital, Bergen (n ¼ 140) and the University Hospital in Stavanger, (n ¼ 72), Norway. All patients fulfilled the American-European consensus criteria 58 and all patients included in the study were Caucasians. After genotype quality controls where individuals with a genotype success rate of o90% were excluded, 540 cases and 532 controls were subjected to further study. The controls were matched for age, gender and geographical area and consisted of healthy blood donors from Uppsala and Linkö ping (n ¼ 88) in Sweden, and from Bergen and Stavanger (n ¼ 213) in Norway. The controls from Malmö (n ¼ 143) consisted of a population based cohort included in the Malmö Cost-Cancer registry and the controls from Stockholm (n ¼ 88) were samples from the populationbased Epidemiological Investigation of Rheumatoid Arthritis (EIRA) control cohort. In the population-based EIRA control cohort, a genome-wide scan with Illumina (Illumina Inc., San Diego, CA, USA) Human Hap300 reveals a relatively homogenous population with a genomic control l value of 1.05, which is evidence for a low degree of population admixture. Data on autoantibody profiles were obtained from the patient files. The characteristics of the patients are shown in Table 2 . All patients gave their informed consent and the study was approved by the relevant ethical committees.
Genotyping
The candidate genes selected included genes from all chromosomes except Chr 14, 15 and 21. The genetic variations in the 84 selected candidate genes were covered with Tag-SNPs where r 2 ¼ 0.8 was considered as tagged. The following parameters were used for selecting the Tag-SNPs: (i) genotypes from the HapMap Caucasian (CEU) samples for SNPs with a minor allele frequency 45%, (ii) SNPs with an Illumina design score of 40.4, (iii) 460 bp between SNPs. Genotyping was performed using 250 ng DNA extracted from peripheral blood samples of the study subjects, by the Illumina GoldenGate assay (Illumina Inc.). To ensure consistency in the reporting of genotyping calls for A/T or C/G SNPs we followed Illumina's method for determining strand orientation (http://www.illumina.com/documents/products/technotes/technote_topbot.pdf).
The genotyping success for the samples was on average 90% and the average SNP call rate 91.44%. In all, 28 samples were genotyped in duplicates by the GoldenGate assay (Illumina Inc.) with 100% consistency between genotype calls. The genotype quality control threshold used in the study included SNP call rate 490%, sample genotype rate 490%, minor allele frequency 41% and Hardy-Weinberg equilibrium in the control samples (P40.001). After quality control filtering, 1072 samples out of 1201 (89.26%) and 1139 SNPs out of 1261 (90.33%) genotyped remained for further analysis. The STAT4 SNP rs7582694 had previously been genotyped by a homogenous minisequencing assay with fluorescence polarization detection in 39% of the samples. 9 For these 466 genotypes called by two different methods, the reproducibility was 100%. LD between SNPs was calculated using all controls (n ¼ 532).
Statistical analysis
Allele counts and genotype frequencies in cases and controls were compared using Fisher's exact test to estimate the significance of the association with primary SS for each individual marker. A nominal P-value of o0.001 was considered a significant association while a nominal P-value of o0.01 was considered a suggestive association. Estimation of LD, calculation of ORs, and the Cochran-Mantel-Haenszel test for combining the Swedish and Norwegian cohorts were performed using the PLINK software (http://pngu.mgh.harvard.edu/~purcell/ plink/). The Haploview v.4.1 software (http://www. broadinstitute.org/haploview/) was used to construct LD plots between the genotyped polymorphisms in the combined dataset from the controls. Haploview was also used to determine the pairwise correlation between SNPs in the combined control data and in the HapMap data. The genetic power calculator Quanto was used to calculate the allelic association power of the study using the matched case-control module for discrete traits and an additive inheritance mode (http://hydra.usc.edu/gxe).
